Article Synopsis

  • The study found that fractional anisotropy (FA) is decreased in patients with hypertrophic cardiomyopathy (HCM), indicating disruption in the structure of the heart muscle.
  • FA is associated with the presence of ventricular arrhythmias, suggesting that lower FA increases the risk of these potentially fatal heart rhythms in HCM patients.
  • DT-CMR imaging proves to be a valuable noninvasive tool for assessing heart muscle microstructure and predicting arrhythmia risk in HCM.

Video Abstracts
Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Myocardial disarray is a likely focus for fatal arrhythmia in hypertrophic cardiomyopathy (HCM). This microstructural abnormality can be inferred by mapping the preferential diffusion of water along cardiac muscle fibers using diffusion tensor cardiac magnetic resonance (DT-CMR) imaging. Fractional anisotropy (FA) quantifies directionality of diffusion in 3 dimensions. The authors hypothesized that FA would be reduced in HCM due to disarray and fibrosis that may represent the anatomic substrate for ventricular arrhythmia.

Objectives: This study sought to assess FA as a noninvasive in vivo biomarker of HCM myoarchitecture and its association with ventricular arrhythmia.

Methods: A total of 50 HCM patients (47 ± 15 years of age, 77% male) and 30 healthy control subjects (46 ± 16 years of age, 70% male) underwent DT-CMR in diastole, cine, late gadolinium enhancement (LGE), and extracellular volume (ECV) imaging at 3-T.

Results: Diastolic FA was reduced in HCM compared with control subjects (0.49 ± 0.05 vs. 0.52 ± 0.03; p = 0.0005). Control subjects had a mid-wall ring of high FA. In HCM, this ring was disrupted by reduced FA, consistent with published histology demonstrating that disarray and fibrosis invade circumferentially aligned mid-wall myocytes. LGE and ECV were significant predictors of FA, in line with fibrosis contributing to low FA. Yet FA adjusted for LGE and ECV remained reduced in HCM (p = 0.028). FA in the hypertrophied segment was reduced in HCM patients with ventricular arrhythmia compared to patients without (n = 15; 0.41 ± 0.03 vs. 0.46 ± 0.06; p = 0.007). A decrease in FA of 0.05 increased odds of ventricular arrhythmia by 2.5 (95% confidence interval: 1.2 to 5.3; p = 0.015) in HCM and remained significant even after correcting for LGE, ECV, and wall thickness (p = 0.036).

Conclusions: DT-CMR assessment of left ventricular myoarchitecture matched patterns reported previously on histology. Low diastolic FA in HCM was associated with ventricular arrhythmia and is likely to represent disarray after accounting for fibrosis. The authors propose that diastolic FA could be the first in vivo marker of disarray in HCM and a potential independent risk factor.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548973PMC
http://dx.doi.org/10.1016/j.jacc.2019.02.065DOI Listing

Publication Analysis

Top Keywords

reduced hcm
16
control subjects
12
lge ecv
12
ventricular arrhythmia
12
hcm
11
myocardial disarray
8
disarray fibrosis
8
hcm patients
8
years age
8
ventricular
7

Similar Publications

Objective: To evaluate the impact of CT planning on surgical myectomy outcomes in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) and/or mid-cavity obstruction, by comparing these outcomes with those of conventional surgical myectomy.

Methods: This prospective cohort study included patients who underwent surgical septal myectomy for HCM with LVOT and/or mid-cavity obstruction between January 2019 and May 2024 at a single tertiary center. In the CT-planned myectomy group, an expert radiologist simulated the target myectomy site through a series of post-processing methods to plan the surgical approach, provide a surgeon's view that closely resembles the actual perspective in the operating room, and present the target myectomy volume.

View Article and Find Full Text PDF

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.

Circulation

September 2025

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (J.C., C.G., C.N., S.M., I.G., F.M., A.M., C.P., L.R., I.L., N.I., R.M., G.D.L.).

Background: Post-exercise oxygen uptake recovery (VORec) is slow in advanced heart failure. We sought to establish easily derived VORec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VORec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.

View Article and Find Full Text PDF

Background: Doxorubicin (Dox) is a chemotherapy medication used in the therapy of cancers. However, despite its killing of cancer cells, Dox is toxic to the heart and can lead to heart failure. This outcome in turn poses a therapeutic challenge given the limited treatment options available to these individuals.

View Article and Find Full Text PDF

Electromechanically Optimized Right Ventricular Pacing for Obstructive Hypertrophic Cardiomyopathy (EMORI-HCM).

J Am Coll Cardiol

August 2025

National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK; London North West University Healthcare NHS Trust, Watford Road, Harrow, HA1 3UJ, UK. Electronic address:

Background: Many patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) have devices capable of right ventricular pacing (RVP). Although pacing can reduce left ventricular outflow tract gradient (LVOTg), it can also reduce cardiac output, so its net effect is variable.

Objective: We tested whether electromechanical optimisation of the programmed atrio-ventricular delay (AVD) allows RVP to achieve a net benefit on symptoms.

View Article and Find Full Text PDF

Background: Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract gradients, improves exercise capacity, and decreases HCM symptoms when added to standard medications. Whether aficamten as monotherapy provides greater clinical benefit than beta-blockers as monotherapy remains unknown.

View Article and Find Full Text PDF